BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring
Could it become as successful in this niche as it was in the coronavirus vaccine market?
Quick take
Read original at Yahoo Finance BioNTech is targeting the $516.2 billion oncology market, expected to grow at a 9.3% compound annual rate by 2035. The company has over 25 ongoing oncology clinical trials, including a promising bispecific antibody called pumitamig, developed with Bristol Myers Squibb. BioNTech aims to carve out a niche in this large therapeutic area.
Summarised by netranta from Yahoo Finance. Open the original for the full story.
Observations (0)
Log in to add an observation.
No observations yet — add the first.